Choksi Laborator

Should I buy, sell or hold Choksi Laboratories Ltd?

Which are the latest news on Choksi Laborator?

Who are in the management team of Choksi Laborator?

The management team of Choksi Laborator includes Sunil Choksi (Managing Director & CEO), Stela Choksi (Whole-time Director), Vyangesh Choksi (Whole Time Director & CFO), Himik Choksi (Whole-time Director), and Prakhar Dubey (Company Secretary & Compliance Officer), along with independent directors Sudarshan Shastri, N K Mani, Raghmendra Singh, and Meenaxi Patidar. This team is responsible for the company's governance and strategic direction.

The management team of Choksi Laborator includes the following individuals:<BR><BR>1. **Sunil Choksi** - Managing Director & CEO<BR>2. **Stela Choksi** - Whole-time Director<BR>3. **Vyangesh Choksi** - Whole Time Director & CFO<BR>4. **Himik Choksi** - Whole-time Director<BR>5. **Prakhar Dubey** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors:<BR><BR>1. **Sudarshan Shastri** - Independent Director<BR>2. **N K Mani** - Independent Director<BR>3. **Raghmendra Singh** - Independent Director<BR>4. **Meenaxi Patidar** - Independent Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Choksi Laborator do?

Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare sector, with a market cap of INR 83 Cr. As of June 2026, it reported net sales of 12 Cr and a net profit of 1 Cr.

Overview:<BR>Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Choksi Laboratories Ltd was incorporated on 29 January 1993. The latest quarterly results reported net sales and profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 12 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 83 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 48.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.20 <BR>Return on Equity: 6.69% <BR>Price to Book: 3.21 <BR><BR>Contact Details:<BR>Address: Survey no 9/1 Gram Kumerdi, Near to Tulshiyana Indl Park Indore Madhya Pradesh : 452010 <BR>Email: compliance_officer@choksi.com <BR>Website: http://www.choksilab.com

Who are the peers of the Choksi Laborator?

Choksi Laborator's peers include Jeevan Scienti, Bilcare, Aspira Pathlab, Shree Pacetronix, Royal Sense, KMS Medisurgi, and Aakaar Medical. Choksi has a Below Average management risk and a 1-year return of -44.64%, significantly lower than its peers, with Royal Sense showing the highest return at 96.95%.

Peers: The peers of Choksi Laborator are Jeevan Scienti., Bilcare, Aspira Pathlab, Shree Pacetronix, Royal Sense, KMS Medisurgi, and Aakaar Medical.<BR><BR>Quality Snapshot: Below Average management risk is observed at Jeevan Scienti., Bilcare, Aspira Pathlab, and Choksi Laborator, while Good management risk is found at Shree Pacetronix, Royal Sense, and Aakaar Medical. Growth is rated as Excellent at Royal Sense, Good at Choksi Laborator, Shree Pacetronix, and Aakaar Medical, and Below Average at Jeevan Scienti., Bilcare, Aspira Pathlab, and KMS Medisurgi. Capital Structure is rated as Good at Shree Pacetronix, Royal Sense, and KMS Medisurgi, Average at Choksi Laborator and Aspira Pathlab, and Below Average at Jeevan Scienti. and Bilcare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Jeevan Scienti. at 96.95%, while the lowest is Choksi Laborator at -44.64%. Choksi Laborator's 1-year return is significantly lower than that of its peers. Additionally, the six-month return is negative for Shree Pacetronix, Royal Sense, and Choksi Laborator.

How big is Choksi Laborator?

As of 14th August, Choksi Laboratories Ltd has a market capitalization of 86.23 Cr, with recent net sales of 46.82 Cr and a net profit of 2.16 Cr.

As of 14th August, Choksi Laboratories Ltd has a market capitalization of 86.23 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Choksi Laboratories reported Net Sales of 46.82 Cr and a Net Profit of 2.16 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 23.60 Cr and Total Assets of 64.79 Cr.

Why is Choksi Laboratories Ltd falling/rising?

As of 14-Aug, Choksi Laboratories Ltd's stock price has risen to Rs 123.80, reflecting a 4.96% increase. Despite a significant drop in investor participation, the stock has outperformed its sector and benchmark, showing a positive trend over recent days and weeks.

As of 14-Aug, Choksi Laboratories Ltd is experiencing a rise in its stock price, currently at Rs 123.80, which reflects an increase of Rs 5.85 or 4.96%. This upward movement is supported by several factors. The stock has outperformed its sector by 2.9% today and has shown a consecutive gain over the last two days, accumulating a total return of 6.59% during this period. Additionally, the stock opened with a gain of 4.96% today and reached an intraday high of Rs 123.80.<BR><BR>In terms of performance relative to the benchmark, Choksi Laboratories has demonstrated strong returns over the past week, with a gain of 4.74%, while the Sensex has declined by 0.62%. Over the past month, the stock has increased by 7.65%, contrasting with the Sensex's modest gain of 1.24%. Furthermore, the stock is trading above its moving averages across various time frames, indicating a positive trend.<BR><BR>However, it is important to note that there has been a significant decline in investor participation, with delivery volume dropping by 88.13% compared to the five-day average. Despite this, the overall performance metrics suggest that the stock is currently on an upward trajectory.

When is the next results date for Choksi Laboratories Ltd?

The next results date for Choksi Laboratories Ltd is August 13, 2026.

The next results date for Choksi Laboratories Ltd is scheduled for August 13, 2026.

Are Choksi Laboratories Ltd latest results good or bad?

Choksi Laboratories Ltd's latest Q4 FY26 results show a significant net profit increase of 232.26% and revenue growth of 12.46%, but concerns remain due to low return on equity (6.50%) and a high debt-to-EBITDA ratio (4.91), indicating underlying financial weaknesses. Overall, while there are positive signs, the results are mixed and warrant caution for investors.

Choksi Laboratories Ltd's latest results for Q4 FY26 show a mixed picture. On the positive side, the company reported a net profit of ₹1.03 crores, which is a significant increase of 232.26% compared to the previous quarter. Additionally, revenue grew by 12.46% year-on-year, reaching ₹12.82 crores, and the operating margin improved to 28.39%, up from 24.49% in the previous quarter.<BR><BR>However, there are notable concerns. The return on equity (ROE) remains low at 6.50%, indicating weak capital efficiency. The company also has a high debt-to-EBITDA ratio of 4.91 times, which raises questions about its financial stability. Furthermore, while the quarterly results show improvement, the annual profit stagnated at ₹1.00 crore, unchanged from the previous year, suggesting challenges in translating revenue growth into meaningful profit expansion.<BR><BR>In summary, while there are positive signs in the recent quarterly performance, underlying structural weaknesses and high leverage indicate that the overall results are not entirely favorable. Investors should weigh these factors carefully.

How has been the historical performance of Choksi Laborator?

Choksi Laborator has experienced growth in net sales and operating income from Mar'21 to Mar'25, but its profitability metrics, including profit before and after tax, have fluctuated significantly. The company needs to focus on cost management and operational efficiency despite improved cash flow from operating activities.

Answer:<BR>The historical performance of Choksi Laborator shows a mixed trend over the years, with notable fluctuations in revenue and profitability.<BR><BR>Breakdown:<BR>Choksi Laborator's net sales have shown a consistent upward trajectory, increasing from 25.69 Cr in Mar'21 to 41.78 Cr in Mar'25. Total operating income followed a similar pattern, rising from 28.49 Cr in Mar'20 to 41.78 Cr in Mar'25. The company's operating profit (PBDIT) has also improved, reaching 11.30 Cr in Mar'25 from 3.17 Cr in Mar'20, although the operating profit margin has slightly decreased from 29.73% in Mar'23 to 26.88% in Mar'25. Profit before tax fluctuated significantly, peaking at 3.72 Cr in Mar'23 before dropping to 2.15 Cr in Mar'25. Profit after tax also saw a decline from 3.21 Cr in Mar'23 to 1.52 Cr in Mar'25. The company's total liabilities increased from 59.49 Cr in Mar'23 to 64.79 Cr in Mar'25, while total assets rose from 59.49 Cr to 64.79 Cr in the same period. Cash flow from operating activities improved to 11.00 Cr in Mar'25, maintaining stability compared to previous years. Overall, while Choksi Laborator has shown growth in sales and operating income, its profitability metrics have experienced volatility, indicating a need for strategic focus on cost management and operational efficiency.

Is Choksi Laborator overvalued or undervalued?

As of October 13, 2025, Choksi Laborator is rated attractive but considered overvalued with high valuation ratios, including a PE of 85.25, despite strong stock performance, especially when compared to peers like Apollo Hospitals and Max Healthcare.

As of 13 October 2025, the valuation grade for Choksi Laborator has moved from very attractive to attractive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 85.25, while the Price to Book Value is 5.42, and the EV to EBIT is 33.62, all indicating a premium valuation compared to its peers.<BR><BR>In comparison, Apollo Hospitals, which is also rated attractive, has a significantly lower PE ratio of 70.2 and an EV to EBITDA of 36.12. Max Healthcare, rated as very expensive, has a PE ratio of 92.33, but its high valuation does not justify the premium over Choksi Laborator. Despite Choksi's impressive stock performance, with a year-to-date return of 144.57% compared to the Sensex's 5.36%, the elevated valuation ratios suggest that the stock may be overvalued in the current market environment.

Who are the top shareholders of the Choksi Laborator?

The top shareholders of Choksi Laborator include promoter Sunil Choksi with 7.51% and public shareholder Sachin Seth with 3.96%. Individual investors hold 52.67%, while foreign institutional investors own 1.94%, and there are no mutual funds invested in the company.

The top shareholders of Choksi Laborator include Sunil Choksi, who is the promoter with the highest holding at 7.51%. Following him, Sachin Seth is the highest public shareholder with a stake of 3.96%. Additionally, individual investors collectively hold a significant portion of the company at 52.67%. The company also has 1.94% held by foreign institutional investors (FIIs), but there are no mutual funds currently invested in it.

What is the technical trend for Choksi Laborator?

As of June 3, 2025, Choksi Laborator's technical trend has shifted to bullish, supported by strong daily moving averages and monthly indicators, despite some mildly bearish signals on the weekly MACD and KST.

As of 3 June 2025, the technical trend for Choksi Laborator has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands confirm a bullish trend. Despite the weekly MACD and KST showing mildly bearish signals, the monthly MACD and KST are bullish, reinforcing the overall positive outlook. Dow Theory also indicates a bullish trend on both weekly and monthly time frames. The stock has shown significant returns compared to the Sensex, further highlighting its strength in the market.

Has Choksi Laborator declared dividend?

No Dividend History Available